Company Guizhou Yibai Pharmaceutical Co., Ltd.

600594

CNE000001H03

Pharmaceuticals

End-of-day quote Shanghai S.E. Other stock markets 2025-07-11			5-day change	1st Jan Change
4.110 ^CNY	+0.49%		+1.99%	+15.45%

Apr. 25	Guizhou Yibai Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2025	CI
2024	Guizhou Yibai Pharmaceutical Co., Ltd. 's Equity Buyback announced on November 29, 2023 has expired.	CI

Business description: Guizhou Yibai Pharmaceutical Co., Ltd.

Guizhou Yibai Pharmaceutical Co Ltd is a China-based company principally engaged in pharmaceutical industry, medical services, and big health industry businesses. The pharmaceutical industry business is mainly engaged in the research and development, production and sales of chemical drugs, traditional Chinese medicines, biological drugs and other drugs. The medical service business is mainly engaged in the operation and management of comprehensive hospitals, tumor specialty hospitals, and tumor radiotherapy centers. The big health industry business is mainly engaged in the development, research, production and sales of big health products featuring Miao medicine. The Company mainly operates its businesses in the domestic market.

Number of employees: 5,261

Sales by Activity: Guizhou Yibai Pharmaceutical Co., Ltd.

Fiscal Period: December	2020	2021	2022	2023	2024
Pharmaceutical Industry	2.98B	2.96B	2.27B	2.35B	1.68B
Medical Services	427M	381M	457M	458M	467M

See all business segments

Geographical breakdown of sales: Guizhou Yibai Pharmaceutical Co., Ltd.

Fiscal Period: December	2020	2021	2022	2023	2024
China	3.41B	3.35B	2.74B	2.82B	2.17B

See all geographic segments

Executive Committee: Guizhou Yibai Pharmaceutical Co., Ltd.

Manager	Title	Age	Since
Ya Qi Dou CEO	Chief Executive Officer	41	2021-05-12
Xian Hong Jiang DFI	Director of Finance/CFO	40	2020-03-22
Zhi Wei Wang PRN	Corporate Officer/Principal	55	2019-09-16
Guang Xin Zhou IRC	Investor Relations Contact	-	-

See GUIZHOU YIBAI PHARMACEUTICAL CO., LTD. governance

Composition of the Board of Directors: Guizhou Yibai Pharmaceutical Co., Ltd.

Director	Title	Age	Since
Qi Ling Dou CHM	Chairman	65	2009-01-21
Zhi Wei Wang BRD	Director/Board Member	55	2011-02-20
Ya Qi Dou BRD	Director/Board Member	41	2019-01-02
Wen Zong Peng BRD	Director/Board Member	53	2013-06-26
Tao Jiang CHM	Chairman	45	2021-05-12
Jian Pu BRD	Director/Board Member	47	2021-05-12
Jian Qiong Liang BRD	Director/Board Member	43	2019-09-16
Qin Song BRD	Director/Board Member	69	2023-06-29
Yi Song Chen BRD	Director/Board Member	53	2023-06-29

Composition of the Board of Directors

Shareholders: Guizhou Yibai Pharmaceutical Co., Ltd.

Name	Equities	%	Valuation
Wanjia Asset Management Co., Ltd. 0.1091 %	863,700	0.1091 %	464 066 ¥
Zhong Ou Asset Management Co., Ltd 0.1016 %	804,900	0.1016 %	432 473 ¥
Guotai Asset Management Co., Ltd. 0.094 %	744,600	0.094 %	400 074 ¥
China Europe Fund Management Co., Ltd. 0.0173 %	136,900	0.0173 %	73 556 ¥
Nuode Asset Management Co., Ltd. 0.0158 %	124,870	0.0158 %	67 093 ¥

List of GUIZHOU YIBAI PHARMACEUTICAL CO., LTD. shareholders

Company details: Guizhou Yibai Pharmaceutical Co., Ltd.

Guizhou Yibai Pharmaceutical Co., Ltd.

No. 220-1 Baiyun Avenue Yunyan District

550008, Guiyang

+86 85 1847 05590

http://www.gzcci.com

address Guizhou Yibai Pharmaceutical Co., Ltd.(600594)

Other Pharmaceuticals

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5d. change	1-year change	3-years change	Capi.($)
GUIZHOU YIBAI PHARMACEUTICAL CO., LTD.	+0.49%	+1.99%	+34.31%	-25.68%	450M
ELI LILLY AND COMPANY	+0.30%	+1.58%	-16.38%	+145.07%	712B
JOHNSON & JOHNSON	-0.50%	+0.57%	+4.68%	-10.78%	378B
ABBVIE INC.	-1.31%	+1.67%	+13.02%	+26.23%	340B
NOVO NORDISK A/S	-3.64%	-2.74%	-55.22%	+8.38%	305B
ROCHE HOLDING AG	-2.36%	-1.23%	+0.78%	-21.80%	259B
NOVARTIS AG	-3.00%	-1.93%	-3.83%	+16.05%	237B
ASTRAZENECA PLC	-1.66%	+1.10%	-14.76%	-6.40%	219B
MERCK & CO., INC.	-0.79%	+3.00%	-34.75%	-10.94%	209B
AMGEN INC.	-1.70%	-1.00%	-10.75%	+19.56%	159B
Average	-1.42%	+0.67%	-8.29%	+13.97%	281.75B
Weighted average by Cap.	-1.30%	+0.64%	-12.51%	+38.42%